Browse NDUFA9

Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix
Domain PF01370 NAD dependent epimerase/dehydratase family
Function

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.

> Gene Ontology
 
Biological Process GO:0006091 generation of precursor metabolites and energy
GO:0006119 oxidative phosphorylation
GO:0006120 mitochondrial electron transport, NADH to ubiquinone
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006743 ubiquinone metabolic process
GO:0006744 ubiquinone biosynthetic process
GO:0006814 sodium ion transport
GO:0009108 coenzyme biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0010257 NADH dehydrogenase complex assembly
GO:0015672 monovalent inorganic cation transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0022900 electron transport chain
GO:0022904 respiratory electron transport chain
GO:0032981 mitochondrial respiratory chain complex I assembly
GO:0033108 mitochondrial respiratory chain complex assembly
GO:0042180 cellular ketone metabolic process
GO:0042181 ketone biosynthetic process
GO:0042278 purine nucleoside metabolic process
GO:0042773 ATP synthesis coupled electron transport
GO:0042775 mitochondrial ATP synthesis coupled electron transport
GO:0044283 small molecule biosynthetic process
GO:0045333 cellular respiration
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0097031 mitochondrial respiratory chain complex I biogenesis
GO:1901004 ubiquinone-6 metabolic process
GO:1901006 ubiquinone-6 biosynthetic process
GO:1901657 glycosyl compound metabolic process
GO:1901661 quinone metabolic process
GO:1901663 quinone biosynthetic process
Molecular Function GO:0003954 NADH dehydrogenase activity
GO:0008137 NADH dehydrogenase (ubiquinone) activity
GO:0016651 oxidoreductase activity, acting on NAD(P)H
GO:0016655 oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor
GO:0048037 cofactor binding
GO:0050136 NADH dehydrogenase (quinone) activity
GO:0050662 coenzyme binding
Cellular Component GO:0005743 mitochondrial inner membrane
GO:0005746 mitochondrial respiratory chain
GO:0005747 mitochondrial respiratory chain complex I
GO:0005759 mitochondrial matrix
GO:0030964 NADH dehydrogenase complex
GO:0044455 mitochondrial membrane part
GO:0045271 respiratory chain complex I
GO:0070469 respiratory chain
GO:0098798 mitochondrial protein complex
GO:0098800 inner mitochondrial membrane protein complex
GO:0098803 respiratory chain complex
GO:1990204 oxidoreductase complex
> KEGG and Reactome Pathway
 
KEGG hsa04723 Retrograde endocannabinoid signaling
hsa00190 Oxidative phosphorylation
hsa01100 Metabolic pathways
Reactome R-HSA-6799198: Complex I biogenesis
R-HSA-1430728: Metabolism
R-HSA-611105: Respiratory electron transport
R-HSA-163200: Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
R-HSA-1428517: The citric acid (TCA) cycle and respiratory electron transport
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NDUFA9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NDUFA9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NDUFA9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0420.808
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0380.988
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0980.958
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1190.742
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1680.905
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.050.975
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.080.836
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0990.954
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0660.972
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3620.837
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0660.98
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1930.00265
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NDUFA9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NDUFA9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NDUFA9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NDUFA9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NDUFA9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NDUFA9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NDUFA9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNDUFA9
NameNADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa
Aliases SDR22E1; CI-39k; short chain dehydrogenase/reductase family 22E, member 1; complex I 39kDa subunit; NDUFS2L; ......
Chromosomal Location12p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NDUFA9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NDUFA9.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB03147Flavin adenine dinucleotideSmall MoleculeACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ......26